AEON Biopharma (AEON) AI Stock Analysis

• Market Cap: $13.41M
• Dividend Yield: N/A
• Average Volume (3M): 273.24K
• Price to Earnings (P/E): 0.2
• Beta (1Y): 1.39
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.39
• Shares Outstanding: 12,105,902
• 10 Day Avg. Volume: 605,674
• 30 Day Avg. Volume: 273,237
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.04
• Enterprise Value/Market Cap: 1.23
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $1.00 ▼(-9.09% Downside)

The score is held down primarily by weak financial fundamentals—limited/absent revenue, persistent cash burn, and negative equity that increases funding and solvency risk. Offsetting this, technical indicators show moderate positive momentum with price above key moving averages and a positive MACD. Valuation appears low on P/E, but its usefulness is constrained by volatile/limited earnings and lack of dividend support.

Positive Factors

Therapeutic Focus

AEON's focus on unmet medical needs in neurological and gastroenterological disorders positions it well in a niche market with high demand potential.

Strategic Partnerships

Strategic partnerships can provide milestone payments and royalties, offering potential revenue streams and enhancing AEON's market reach and financial stability.

Product Development

Progress in clinical trials for therapeutic applications can lead to future regulatory approvals and commercialization, driving long-term revenue growth.

Negative Factors

Financial Distress

Ongoing financial distress with consistent losses and negative cash flows poses a significant risk to AEON's ability to sustain operations and invest in growth.

Negative Equity

Negative equity suggests liabilities exceed assets, raising concerns about AEON's solvency and long-term financial health, potentially limiting future investment.

Cash Flow Challenges

Negative cash flow and reliance on external financing indicate unsustainable operations, threatening AEON's ability to fund R&D and achieve profitability.

AEON Biopharma Business Overview & Revenue Model

Company Description

AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.

How the Company Makes Money

AEON Biopharma makes money primarily through the development and eventual commercialization of its therapeutic products. The company generates revenue by advancing its drug candidates through clinical trials, securing regulatory approvals, and subsequently marketing these drugs to healthcare providers and institutions. Key revenue streams include potential product sales, licensing agreements, and strategic partnerships with other pharmaceutical companies that may provide milestone payments and royalties. AEON's financial success is significantly influenced by the outcomes of its clinical trials and its ability to navigate the regulatory landscape effectively.

AEON Biopharma Financial Statement Overview

Summary

AEON Biopharma's financial health is precarious, marked by consistent losses, deteriorating equity position, and negative cash flows. The company faces significant challenges in achieving profitability and maintaining financial stability, with high risk of continued financial distress.

Income Statement

AEON Biopharma shows a lack of revenue generation with consistent negative EBIT and net income across the years. The absence of revenue growth and profitability highlights challenges in achieving operational efficiency and market penetration.

Balance Sheet

The balance sheet reflects significant financial distress with a negative stockholders' equity, indicating potential insolvency issues. The company's liabilities exceed its assets, suggesting a high-risk financial position.

Cash Flow

Negative free cash flow and operating cash flow indicate ongoing cash burn without revenue generation. The reliance on financing activities for liquidity suggests unsustainable financial operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	2.52M
Gross Profit	0.00	0.00	0.00	0.00	0.00	2.52M
EBITDA	-16.39M	-27.73M	-52.74M	-48.36M	-36.88M	-15.51M
Net Income	-3.00K	42.01M	-384.63M	-52.56M	-55.64M	-32.91M
Balance Sheet
Total Assets	8.73M	3.14M	6.84M	10.78M	6.44M	21.21M
Cash, Cash Equivalents and Short-Term Investments	5.93M	13.00K	5.16M	9.75M	5.13M	20.17M
Total Debt	18.25M	12.96M	278.00K	131.53M	86.89M	72.16M
Total Liabilities	28.61M	31.71M	159.89M	281.19M	230.26M	224.45M
Stockholders Equity	-19.87M	-28.57M	-153.04M	-287.50M	-234.94M	-208.27M
Cash Flow
Free Cash Flow	-13.22M	-20.29M	-47.83M	-35.89M	-28.60M	-9.46M
Operating Cash Flow	-13.22M	-20.29M	-47.83M	-35.58M	-28.43M	-9.46M
Investing Cash Flow	-4.00K	0.00	0.00	-306.00K	-170.00K	-1.26M
Financing Cash Flow	18.61M	15.15M	14.00M	40.51M	13.56M	24.57M

AEON Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AEON, the sentiment is Positive. The current price of 1.1 is above the 20-day moving average (MA) of 1.08, above the 50-day MA of 0.95, and above the 200-day MA of 0.78, indicating a bullish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 60.54 is Neutral, neither overbought nor oversold. The STOCH value of 42.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AEON.

AEON Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AEON	52 Neutral	$13.41M	0.23	―	―	―	―
GLTO	52 Neutral	$39.92M	-1.98	-114.81%	―	―	37.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMNN	48 Neutral	$12.41M	-0.34	-233.50%	―	―	57.97%
RNAZ	44 Neutral	$8.27M	-0.04	-1763.01%	―	―	96.75%
APM	42 Neutral	$8.63M	-2.99	-9.02%	―	―	-1979.68%
XTLB	39 Underperform	$8.13M	-8.68	―	―	―	65.45%

AEON Biopharma Corporate Events

AEON Biopharma Releases Updated Investor Presentation Under Reg FD

On January 12, 2026, AEON Biopharma, Inc. made a new corporate presentation available in the investor relations section of its website and indicated that management may use this material in future meetings about the company. The company emphasized that the information in this presentation, while informative for investors and other stakeholders, is being furnished rather than filed for securities law purposes, meaning it is not subject to certain Exchange Act liabilities and will only be incorporated into other regulatory filings if specifically referenced, a distinction that shapes the legal framework around how the disclosed information can be relied upon.

The most recent analyst rating on (AEON) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on AEON Biopharma stock, see the AEON Stock Forecast page.

AEON Biopharma Announces Exchange Agreement with Daewoong

On December 15, 2025, AEON Biopharma Inc. announced an Exchange Agreement with Daewoong Pharmaceuticals, involving the exchange of previously issued convertible notes for common stock, a new convertible note, and warrants. This agreement, subject to stockholder approval, aims to strengthen AEON’s financial position and involves Daewoong nominating a director to AEON’s board, potentially impacting the company’s governance and market strategy.

AEON Biopharma Releases New Corporate Presentation

On December 4, 2025, AEON Biopharma, Inc. released a corporate presentation in the investor relations section of its website. This presentation, which is also part of a Current Report on Form 8-K, is intended for use by the company’s management in future meetings and is not considered filed under the Securities Exchange Act of 1934.

AEON Biopharma Announces New Securities Purchase Agreement

On November 12, 2025, AEON Biopharma entered into a Securities Purchase Agreement with investors for a private placement involving the issuance of common stock and warrants, with the first closing expected the week of November 17, 2025. The agreement includes a second closing contingent on stockholder approval and other conditions, and involves a term sheet with Daewoong Pharmaceutical for exchanging existing notes, potentially impacting the company’s financial structure and market positioning.